NCI | Technology Transfer

Synergistic Interactions For Improved Cancer Treatment

Read more about Synergistic Interactions For Improved Cancer Treatment

European Patent
23768747.0
Filed on 2025-01-29

Synergistic Interactions For Improved Cancer Treatment

Read more about Synergistic Interactions For Improved Cancer Treatment

US Application 19/101,938
Filed on 2025-02-07

SINGLE DOMAIN ANTIBODIES TARGETING HPV E6/E7 ONCOGENIC PEPTIDE/MHC
COMPLEXES

Read more about SINGLE DOMAIN ANTIBODIES TARGETING HPV E6/E7 ONCOGENIC PEPTIDE/MHC COMPLEXES

US Application 19/107,498
Filed on 2025-02-27

PREDICTING PATIENT RESPONSE TO CANCER THERAPY VIA HISTOPATHOLOGY IMAGES

Read more about PREDICTING PATIENT RESPONSE TO CANCER THERAPY VIA HISTOPATHOLOGY IMAGES

India
202417104351
Filed on 2024-12-30

T CELL RECEPTORS RECOGNIZING R175H OR Y220C MUTATION IN P53

Read more about T CELL RECEPTORS RECOGNIZING R175H OR Y220C MUTATION IN P53

Japan
2025-020882
Filed on 2025-02-12

TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21

Read more about TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21

Hong Kong
42025102573.0
Filed on 2025-01-22

NANOPARTICLE-HYDROGEL COMPOSITE FOR NUCLEIC ACID MOLECULE DELIVERY

Read more about NANOPARTICLE-HYDROGEL COMPOSITE FOR NUCLEIC ACID MOLECULE DELIVERY

United Kingdom
19707555.9
Filed on 2019-02-08

NANOPARTICLE-HYDROGEL COMPOSITE FOR NUCLEIC ACID MOLECULE DELIVERY

Read more about NANOPARTICLE-HYDROGEL COMPOSITE FOR NUCLEIC ACID MOLECULE DELIVERY

Germany
19707555.9
Filed on 2019-02-08

NANOPARTICLE-HYDROGEL COMPOSITE FOR NUCLEIC ACID MOLECULE DELIVERY

Read more about NANOPARTICLE-HYDROGEL COMPOSITE FOR NUCLEIC ACID MOLECULE DELIVERY

France
19707555.9
Filed on 2019-02-08

HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS

Read more about HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS

South Korea
10-2025-7006999
Filed on 2025-02-28

Subscribe to NCI